about
A recommendation for revised dose calibrator measurement procedures for 89Zr and 124IImage-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats.Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy.Image deconvolution in digital autoradiography: a preliminary study.High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.Bone marrow dosimetry using 124I-PET.124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.(124)I-huA33 antibody PET of colorectal cancer.Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.Hypoxia in microscopic tumors.Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerPreclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging.Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluoresceIn vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia.First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.Corrigendum to "Noninvasive Multimodality Imaging of the Tumor Microenvironment: Registered Dynamic Magnetic Resonance Imaging and Positron Emission Tomography Studies of a Preclinical Tumor Model of Tumor Hypoxia" [Neoplasia 11 (2009) 247-259]Iodination of annexin V for imaging apoptosis.
P50
Q28542889-2F3E0866-25DE-42DF-8010-F8C2A2864250Q30559873-A2EE2EB6-3212-4F7A-AF86-CA45279F8F46Q33294222-55143BB4-4F2C-4E8C-83DB-FAE22CFC3178Q33326692-AF6EB3DD-B6E8-4464-8F3E-A45A031B0083Q33547295-757C1FA9-0172-4BD3-9CB8-DC01C788D5FCQ33723814-9A141507-EE9F-4BAA-A1C7-90A6D2BE8D55Q33789188-B0AB67C7-7784-441C-A56C-27FC1C936539Q33820595-C3424422-F1CC-4E1A-BABC-89D48C04342DQ33850988-9C79BFC1-BE8E-4B08-9EF9-C2A6FAB6F930Q33936624-A8701652-E581-4A57-8193-90B8E6789232Q34555716-1741CE4C-E063-4F8B-AE2A-9D7E9615A2B3Q35587920-AF7E0C0C-8D81-4FB5-A260-74CC566AB9C6Q36079225-42E1574F-8537-47D2-936B-9996E94C193CQ36088136-E6550932-F608-4A4A-B6ED-4FF0F4A3AC95Q36088144-9BD72276-5E2C-4297-B228-26902B5035E3Q36746466-EC18A2FF-E169-4FAB-8194-F54243AF2737Q36911658-CAA5B3E5-45B8-4768-8BFD-A46A381FFA96Q36940477-30BF31AF-F2F7-42DB-A690-15FFEE124D1DQ37109541-52DB870B-7BF5-496E-B6E3-3899F2E5C2B1Q37126963-216073B2-2101-4EBC-BF1E-AF635F2D22EEQ37168396-2ED4DE55-B678-484D-AB6E-89E535440787Q37178234-C3E5A4D5-CE10-4E21-8B28-D3F1B90830C1Q37273125-E1F706B5-373A-475B-AE9A-6FD4D113ED98Q37309920-128B9BD9-A610-482B-99A8-7DCBF0A21E67Q38891132-9776FFB1-EE22-4631-BBA4-05ECEA5F5B0CQ38968830-73CE7C48-6877-44E8-801C-55358AA58BA8Q39000945-1509B8B0-A800-4080-9737-66873791BDA9Q39569086-21C023E4-E592-46CF-A571-D8ECD3713A84Q39712889-B0C14CBF-5084-43DA-8E61-92751D390EF9Q39805806-46D22CE2-36FE-4D7B-B1B9-11B66D403C15Q39828822-59962B7F-A74C-4064-8A95-C3DFA2C82C0CQ40217263-431404C6-2501-4FD1-8A8C-F892CD878EDAQ40358909-5BD6E746-7173-472E-AF21-CA7A6D190F54Q40396298-F4F0494A-230E-4271-AD1A-0B8E3934EB66Q40481696-CA609F49-E271-402A-BB69-4374680E4E21Q40625131-9E91F761-0E53-4658-B4BC-7808D2918B53Q40629326-63F0F501-B5BD-4F6E-9C74-935DF25977E8Q40735810-C738EEE3-E7FC-4F46-B8B5-BA23AF0E5437Q42352784-A67756F3-3D79-4A33-B9E7-80BE487FD9D7Q43982609-B861B5B5-A80D-45AA-81E3-55A1687592EB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joseph A O'Donoghue
@ast
Joseph A O'Donoghue
@en
Joseph A O'Donoghue
@es
Joseph A O'Donoghue
@nl
Joseph A O'Donoghue
@sl
type
label
Joseph A O'Donoghue
@ast
Joseph A O'Donoghue
@en
Joseph A O'Donoghue
@es
Joseph A O'Donoghue
@nl
Joseph A O'Donoghue
@sl
prefLabel
Joseph A O'Donoghue
@ast
Joseph A O'Donoghue
@en
Joseph A O'Donoghue
@es
Joseph A O'Donoghue
@nl
Joseph A O'Donoghue
@sl
P106
P21
P31
P496
0000-0002-2761-0015